Showing 3401-3410 of 4262 results for "".
- Study: Roflumilast cream 0.15% Significantly Reduces Itch, Improves Quality of Lifehttps://practicaldermatology.com/news/study-roflumilast-cream-015-significantly-reduces-itch-improves-quality-life/2468468/New data show that ZORYVE® (Roflumilast) cream 0.15% rapidly alleviates symptoms of atopic dermatitis (AD) and significantly improves patient-reported outcomes, including daily activity, sleep, and emotional well-being, according to Arcutis. The manufacturer announced in a pres
- FDA Clears Accure Laser System for Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-accure-laser-system-acne-vulgaris/2468432/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founder, chairman o
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants
- LEO Pharma Says Anzupgo Launch in Germany Is 'First of Many'https://practicaldermatology.com/news/leo-pharma-says-anzupgo-launch-germany-first-many/2468408/Delgocitinib cream was launched for the first time worldwide in Germany, under the name Anzupgo®, LEO Pharma said in a press release. The drug was approved in September by the European Commission (EC) for the treatment of adult patients with moderate-to-severe chronic hand eczema (CHE), fo
- Study Analyzes Metabolites and ADhttps://practicaldermatology.com/news/study-analyzes-metabolites-and-ad/2468384/Bidirectional two-sample Mendelian randomization (MR) analyses in a study published in Scientific Reports indicated that 22 metabolites and one inflammatory protein (S100A12) were significantly associated with atopic dermatitis (AD) pathogenesis. “The levels of amino acid metaboli
- FDA Approves Otezla for Pediatric Psoriasishttps://practicaldermatology.com/news/fda-approves-otezla-for-pediatric-psoriasis-treatment/2468356/Amgen’s Otezla® (apremilast) has been approved by the U.S. Food and Drug Administration (FDA) for pediatric use in treating moderate to severe plaque psoriasis, making it the first oral option for this condition in children. The approval, which to patients ages 6 and older who weigh at lea
- TRuE AD3: Ruxolitinib Safety and Efficacy Confirmed in Children with Atopic Dermatitishttps://practicaldermatology.com/news/52-week-study-validates-ruxolitinibs-safety-and-efficacy-in-children-with-ad/2468353/Ruxolitinib cream (RUX) demonstrated long-term safety and efficacy in children aged 2 to 11 with mild-to-moderate atopic dermatitis (AD), with over 60% of patients achieving clear or nearly clear skin, according to updated data presented recently at the 2024 European Academy of Dermatology and Ve
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte